Novel c-Myc-Targeting Compound

Antineoplastic Agents / chemical synthesis Cell Line, Tumor Cell Survival Drug Resistance, Neoplasm / drug effects Humans K562 Cells Lung Neoplasms / drug therapy Methylamines / chemical synthesis Molecular Structure Proteasome Endopeptidase Complex / metabolism Proteolysis Proto-Oncogene Proteins c-myc / chemistry Ubiquitin / metabolism

Journal

Molecular pharmacology
ISSN: 1521-0111
Titre abrégé: Mol Pharmacol
Pays: United States
ID NLM: 0035623

Informations de publication

Date de publication:
08 2020
Historique:
received: 05 02 2020
accepted: 13 05 2020
pubmed: 4 6 2020
medline: 4 8 2020
entrez: 4 6 2020
Statut: ppublish

Résumé

Aberrant cellular Myc (c-Myc) is a common feature in the majority of human cancers and has been linked to oncogenic malignancies. Here, we developed a novel c-Myc-targeting compound,

Identifiants

DOI: 10.1124/mol.120.119719 PMID: 32487733
pubmed: 32487733
pii: mol.120.119719
doi: 10.1124/mol.120.119719
doi:

Substances chimiques

Antineoplastic Agents 0
MYC protein, human 0
Methylamines 0
Proto-Oncogene Proteins c-myc 0
Ubiquitin 0
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

130-142

Informations de copyright

Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Nicharat Sriratanasak (N)

Department of Pharmacology and Physiology and Cell-based Drug and Health Products Development Research Unit (N.S., K.P., P.C.), Faculty of Pharmaceutical Sciences and Doctor of Philosophy Program in Interdisciplinary Pharmacology, Graduate School (K.P.), Chulalongkorn University, Bangkok, Thailand; Department of Materials Engineering, Faculty of Engineering, Kasetsart University, Ladyao, Chatuchak, Bangkok, Thailand (A.L., W.W.); ivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand (C.V.); and Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (S.L.).

Korrakod Petsri (K)

Department of Pharmacology and Physiology and Cell-based Drug and Health Products Development Research Unit (N.S., K.P., P.C.), Faculty of Pharmaceutical Sciences and Doctor of Philosophy Program in Interdisciplinary Pharmacology, Graduate School (K.P.), Chulalongkorn University, Bangkok, Thailand; Department of Materials Engineering, Faculty of Engineering, Kasetsart University, Ladyao, Chatuchak, Bangkok, Thailand (A.L., W.W.); ivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand (C.V.); and Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (S.L.).

Apirat Laobuthee (A)

Department of Pharmacology and Physiology and Cell-based Drug and Health Products Development Research Unit (N.S., K.P., P.C.), Faculty of Pharmaceutical Sciences and Doctor of Philosophy Program in Interdisciplinary Pharmacology, Graduate School (K.P.), Chulalongkorn University, Bangkok, Thailand; Department of Materials Engineering, Faculty of Engineering, Kasetsart University, Ladyao, Chatuchak, Bangkok, Thailand (A.L., W.W.); ivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand (C.V.); and Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (S.L.).

Worawat Wattanathana (W)

Department of Pharmacology and Physiology and Cell-based Drug and Health Products Development Research Unit (N.S., K.P., P.C.), Faculty of Pharmaceutical Sciences and Doctor of Philosophy Program in Interdisciplinary Pharmacology, Graduate School (K.P.), Chulalongkorn University, Bangkok, Thailand; Department of Materials Engineering, Faculty of Engineering, Kasetsart University, Ladyao, Chatuchak, Bangkok, Thailand (A.L., W.W.); ivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand (C.V.); and Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (S.L.).

Chanida Vinayanuwattikun (C)

Department of Pharmacology and Physiology and Cell-based Drug and Health Products Development Research Unit (N.S., K.P., P.C.), Faculty of Pharmaceutical Sciences and Doctor of Philosophy Program in Interdisciplinary Pharmacology, Graduate School (K.P.), Chulalongkorn University, Bangkok, Thailand; Department of Materials Engineering, Faculty of Engineering, Kasetsart University, Ladyao, Chatuchak, Bangkok, Thailand (A.L., W.W.); ivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand (C.V.); and Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (S.L.).

Sudjit Luanpitpong (S)

Department of Pharmacology and Physiology and Cell-based Drug and Health Products Development Research Unit (N.S., K.P., P.C.), Faculty of Pharmaceutical Sciences and Doctor of Philosophy Program in Interdisciplinary Pharmacology, Graduate School (K.P.), Chulalongkorn University, Bangkok, Thailand; Department of Materials Engineering, Faculty of Engineering, Kasetsart University, Ladyao, Chatuchak, Bangkok, Thailand (A.L., W.W.); ivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand (C.V.); and Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (S.L.) suidjit@gmail.com.

Pithi Chanvorachote (P)

Department of Pharmacology and Physiology and Cell-based Drug and Health Products Development Research Unit (N.S., K.P., P.C.), Faculty of Pharmaceutical Sciences and Doctor of Philosophy Program in Interdisciplinary Pharmacology, Graduate School (K.P.), Chulalongkorn University, Bangkok, Thailand; Department of Materials Engineering, Faculty of Engineering, Kasetsart University, Ladyao, Chatuchak, Bangkok, Thailand (A.L., W.W.); ivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand (C.V.); and Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (S.L.) pithi.ch@gmail.com.
ORCID: 0000-0002-3103-3249

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Cellules › Cellules érythroïdes › Cellules K562 › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Composés chimiques organiques › Amines › Méthylamines › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Proteasome endopeptidase complex › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Métabolisme › Protéolyse › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique hélice-boucle-hélice › Protéines proto-oncogènes c-myc › Novel c-Myc-Targeting Compound
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Ubiquitines › Ubiquitine › Novel c-Myc-Targeting Compound